ReviewPharmaceuticals (Basel, Switzerland)2025
Ferroptosis, a Distinct Form of Cell Death, and Research Progress on Its Modulators.
Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- GSH-Related Enzymes GPx4, Chac1, and GSTs and Redox Regulation of Ferroptosis in Cancer.International journal of molecular sciences · 2026Review
- Fatty Acids in Cancer Therapy: Chemical Conjugates, Nanocarriers, and Therapeutic Opportunities.Molecules (Basel, Switzerland) · 2026Review
- The dual role of the crosstalk between autophagy and ferroptosis in lung cancer treatment: Advances in mechanisms and therapeutic strategies (Review).International journal of molecular medicine · 2026Review
- Silencing of METTL16 protects granulosa cells from the cisplatin-induced ferroptosis in premature ovarian failure.Cell death discovery · 2026Article
- Bioactive Natural Products Targeting Androgen Receptor Signaling in Prostate Cancer: A Systematic Review.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Ferroptosis, an iron-dependent and lipid peroxidation-driven mode of regulated cell death, holds significant pathological significance. Its dysregulation manifests in dual facets: inhibition promotes tumorigenesis, whereas overactivation aggravates neurological disorders and organ injury. This paper systematically reviews the core molecular mechanisms of ferroptosis and provides a comprehensive summary of recent advances in its modulators: inducers classified by targets (GPX4 axis, iron metabolism, lipid metabolism, and GPX4-independent antioxidant pathways) and inhibitors classified by source (synthetic and natural). It places a particular focus on summarizing and analyzing the optimization strategies, mechanisms of action, existing limitations, and future directions for novel ferroptosis modulators, to offer valuable insights for future drug development targeting ferroptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.